Ten days later, with a non-specific antibody therapy against SARS-CoV-2 having been carried out—blood test results were unchanged (leukocytes 5500/μL, platelets 102,000/μL (decreased), IgG 301 mg/dL, IgA 3 mg/dL, IgM 25 mg/dL), but the leukocyte typing showed a 70% decline of B-CLL and a reduction of CD4+ helper T cells. This evidence concerns the gene CD79A and B-cell chronic lymphocytic leukemia.